Effects of postchallenge administration of ST-246 on dissemination of IHD-j-Luc vaccinia virus in normal mice and in immune-deficient mice reconstituted with T cells

Journal of Virology

Volumn 87, Issue 10, 2013, Pages 5564-5576

  Zaitseva, Marina ^a   Shotwell, Elisabeth ^a   Scott, John ^a   Cruz, Stephanie ^a   King, Lisa R ^a   Manischewitz, Jody ^a   Diaz, Claudia G ^a   Jordan, Robert A ^b   Grosenbach, Douglas W ^c   Golding, Hana ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b GILEAD SCIENCES   (United States)

^c SIGA Technologies Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TECOVIRIMAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CELL TRANSFER; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; FEMALE; IMAGE ANALYSIS; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFECTION PREVENTION; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; SURVIVAL RATE; VACCINIA; VACCINIA VIRUS; VIRUS IDENTIFICATION; VIRUS LOAD; VIRUS REPLICATION; WHOLE BODY IMAGING;

ADOPTIVE TRANSFER; ANIMAL STRUCTURES; ANIMALS; ANTIVIRAL AGENTS; BENZAMIDES; DISEASE MODELS, ANIMAL; FEMALE; GENES, REPORTER; IMMUNOCOMPROMISED HOST; ISOINDOLES; LUCIFERASES; MICE; MICE, INBRED BALB C; MICE, NUDE; STAINING AND LABELING; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TREATMENT OUTCOME; VACCINIA; VACCINIA VIRUS; VIRAL LOAD; WHOLE BODY IMAGING;

EID: 84877336422     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03426-12     Document Type: Article

References (31)

1. Henderson DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, Jahrling PB, Hauer J, Layton M, McDade J, Osterholm MT, O'Toole T, Parker G, Perl T, Russell PK, Tonat K. 1999. Smallpox as a biological weapon: medical and public health management. JAMA 281:2127-2137.
2. Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK, Kinkela TL, Blumberg S, Thomassen HA, Pike BL, Fair JN, Wolfe ND, Shongo RL, Graham BS, Formenty P, Okitolonda E, Hensley LE, Meyer H, Wright LL, Muyembe JJ. 2010. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc. Natl. Acad. Sci. U. S. A. 107:16262-16267.
3. Whitley RJ. 2003. Smallpox: a potential agent of bioterrorism. Antivir. Res. 57:7-12.
4. Amanna IJ, Slifka MK, Crotty S. 2006. Immunity and immunological memory following smallpox vaccination. Immunol. Rev. 211:320-337.
5. Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, Sexton GJ, Hanifin JM, Slifka MK. 2003. Duration of antiviral immunity after smallpox vaccination. Nat. Med. 9:1131-1137.
6. Baker RO, Bray M, Huggins JW. 2003. Potential antiviral therapeutics for smallpox, monkeypox, and other orthopoxvirus infections. Antivir. Res. 57:13-23.
7. Belongia EA, Naleway AL. 2003. Smallpox vaccine: the good, the bad, and the ugly. Clin. Med. Res. 1:87-92.
8. Neyts J, De Clercq E. 2003. Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives. Antivir. Res. 57:25-33.
9. Lalezari JP, Stagg RJ, Kuppermann BD, Holland GN, Kramer F, Ives DV, Youle M, Robinson MR, Drew WL, Jaffe HS. 1997. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann. Intern. Med. 126:257-263.
10. Lanier R, Trost L, Tippin T, Lampert B, Robertson A, Foster S, Rose M, Painter W, O'Mahony R, Almond M, Painter G. 2010. Development of CMX001 for the treatment of poxvirus infections. Viruses 2:2740-2762.
11. Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S, Barone L, Burns C, Rhodes G, Tohan S, Huggins JW, Baker RO, Buller RL, Touchette E, Waller K, Schriewer J, Neyts J, DeClercq E, Jones K, Hruby D, Jordan R. 2005. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79:13139-13149.
12. Quenelle DC, Buller RM, Parker S, Keith KA, Hruby DE, Jordan R, Kern ER. 2007. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob. Agents Chemother. 51:689-695.
13. Grosenbach DW, Berhanu A, King DS, Mosier S, Jones KF, Jordan RA, Bolken TC, Hruby DE. 2010. Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice. Proc. Natl. Acad. Sci. U. S. A. 107: 838-843.
14. Huggins J, Goff A, Hensley L, Mucker E, Shamblin J, Wlazlowski C, Johnson W, Chapman J, Larsen T, Twenhafel N, Karem K, Damon IK, Byrd CM, Bolken TC, Jordan R, Hruby D. 2009. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob. Agents Chemother. 53:2620-2625.
15. Jordan R, Chinsangaram J, Bolken TC, Tyavanagimatt SR, Tien D, Jones KF, Frimm A, Corrado ML, Pickens M, Landis P, Clarke J, Marbury TC, Hruby DE. 2010. Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. Antimicrob. Agents Chemother. 54:2560-2566.
16. Lederman ER, Davidson W, Groff HL, Smith SK, Warkentien T, Li Y, Wilkins KA, Karem KL, Akondy RS, Ahmed R, Frace M, Shieh WJ, Zaki S, Hruby DE, Painter WP, Bergman KL, Cohen JI, Damon IK. 2012. Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. J. Infect. Dis. 206:1372-1385.
17. Luker KE, Hutchens M, Schultz T, Pekosz A, Luker GD. 2005. Bioluminescence imaging of vaccinia virus: effects of interferon on viral replication and spread. Virology 341:284-300.
18. Rodriguez JF, Rodriguez D, Rodriguez JR, McGowan EB, Esteban M. 1988. Expression of the firefly luciferase gene in vaccinia virus: a highly sensitive gene marker to follow virus dissemination in tissues of infected animals. Proc. Natl. Acad. Sci. U. S. A. 85:1667-1671.
19. Zaitseva M, Kapnick SM, Meseda CA, Shotwell E, King LR, Manischewitz J, Scott J, Kodihalli S, Merchlinsky M, Nielsen H, Lantto J, Weir JP, Golding H. 2011. Passive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organs. J. Virol. 85:9147-9158.
20. Zaitseva M, Kapnick SM, Scott J, King LR, Manischewitz J, Sirota L, Kodihalli S, Golding H. 2009. Application of bioluminescence imaging to the prediction of lethality in vaccinia virus-infected mice. J. Virol. 83: 10437-10447.
21. Zaitseva M, Kapnick S, Golding H. 2012. Measurements of vaccinia virus dissemination using whole body imaging: approaches for predicting of lethality in challenge models and testing of vaccines and antiviral treatments. Methods Mol. Biol. 890:161-176.
22. Golden JW, Zaitseva M, Kapnick S, Fisher RW, Mikolajczyk MG, Ballantyne J, Golding H, Hooper JW. 2011. Polyclonal antibody cocktails generated usingDNAvaccine technology protect in murine models of orthopoxvirus disease. Virol. J. 8:441.
23. R Development Core Team. 2011. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/.
24. Karupiah G, Coupar B, Ramshaw I, Boyle D, Blanden R, Andrew M. 1990. Vaccinia virus-mediated damage of murine ovaries and protection by virus-expressed interleukin-2. Immunol. Cell Biol. 68(Pt 5):325-333.
25. Kemper AR, Davis MM, Freed GL. 2002. Expected adverse events in a mass smallpox vaccination campaign. Eff. Clin. Pract 5:84-90.
26. Belyakov IM, Earl P, Dzutsev A, Kuznetsov VA, Lemon M, Wyatt LS, Snyder JT, Ahlers JD, Franchini G, Moss B, Berzofsky JA. 2003. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. U. S. A. 100:9458-9463.
27. Edghill-Smith Y, Golding H, Manischewitz J, King LR, Scott D, Bray M, Nalca A, Hooper JW, Whitehouse CA, Schmitz JE, Reimann KA, Franchini G. 2005. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat. Med. 11:740-747.
28. Goulding J, Bogue R, Tahiliani V, Croft M, Salek-Ardakani S. 2012. CD8 T cells are essential for recovery from a respiratory vaccinia virus infection. J. Immunol. 189:2432-2440.
29. Xu R, Johnson AJ, Liggitt D, Bevan MJ. 2004. Cellular and humoral immunity against vaccinia virus infection of mice. J. Immunol. 172:6265-6271.
30. Manischewitz J, King LR, Bleckwenn NA, Shiloach J, Taffs R, Merchlinsky M, Eller N, Mikolajczyk MG, Clanton DJ, Monath T, Weltzin RA, Scott DE, Golding H. 2003. Development of a novel vaccinianeutralization assay based on reporter-gene expression. J. Infect. Dis. 188: 440-448.
31. Seedhom MO, Jellison ER, Daniels KA, Welsh RM. 2009. High frequencies of virus-specific CD8 T-cell precursors. J. Virol. 83:12907-12916.